Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$681.00K$681.00Kderived+10.4% vs Q4 2018 Net Income-$17.83M-$17.83MderivedN/M vs Q4 2018 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$2,345,000N/M Operating Cash Flowderived-$3,268,000N/M Free Cash Flowderived-$3,269,000N/M Margins · derivedOperating margin-344.3%+166.2 pt vs Q4 2018
Net margin-2617.6%−2143.4 pt vs Q4 2018
ended Aug 31, 2019 · filed Nov 27, 2019 · 88 d after period end